Flagship’s Valo takes stab at cloud-based R&D with $96.5M and longitudinal human data

Flagship Pioneering is putting AI-accelerated drug development to the test with Valo Health LLC, whose cloud computing platform is geared to guide everything from target discovery to clinical trial design.

Through Valo, the blue chip biotech firm is placing a bet on the long-debated idea that computers can  slash the time, cost and error rate of drug development, a concept whose loudest proponents have primarily come from the world of tech (see “Andreessen Horowitz Embraces ‘Weak AI’”)...